Myasthenia Gravis Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Myasthenia Gravis Market Overview

Myasthenia gravis is a chronic autoimmune condition that can significantly affect muscle strength and physical function. Its symptoms may fluctuate over time and often interfere with daily activities, mobility, communication, swallowing, and overall quality of life, creating an ongoing need for effective disease management. The market was valued at USD 1.88 Billion in 2025. The growth is supported by increasing disease awareness, improved diagnostic capabilities, advances in targeted therapies, and expanding treatment options. The market includes pharmacological therapies, immunotherapies, surgical interventions, and specialized care across hospitals, clinics, and pharmacies.

Myasthenia Gravis Market Growth Analysis and Key Influencers

Myasthenia Gravis Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Myasthenia Gravis Market Growth Drivers

New Targeted Therapies and Expanded Treatment Access to Strengthen Market Value

The availability of targeted therapies and broader access to advanced treatments are supporting market expansion by addressing persistent unmet needs among patients with uncontrolled disease. For instance, in August 2026, the Scottish Medicines Consortium accepted UCB’s zilucoplan for restricted NHS Scotland use in adults with refractory, anti-acetylcholine receptor antibody-positive generalized disease. At least 1,900 people in Scotland live with this condition, and approximately 80% are anti-acetylcholine receptor antibody positive. Such treatment advances and expanded access are expected to stimulate market growth.

Myasthenia Gravis Market Restraints

Elevated Healthcare Costs Create a Barrier to Broader Market Adoption

The substantial healthcare costs associated with the condition can limit treatment access and increase financial pressure on healthcare systems and patients. According to Sun A. Choi et al., 2025, the condition was associated with incremental first-year healthcare costs of USD 25,799 among commercially insured patients and USD 4,927 among Medicare patients in the United States. These elevated costs may restrict access to advanced therapies and challenge broader market expansion.

Myasthenia Gravis Market Opportunities

Expanding Reimbursement for Targeted Therapies to Create New Growth Potential

The expansion of reimbursement for targeted therapies is creating greater potential for treatment adoption among patients with uncontrolled disease. For instance, in April 2026, the National Institute for Health and Care Excellence recommended rozanolixizumab for certain adults with generalized disease, with interim NHS funding beginning April 29, 2026. The treatment could benefit approximately 800 adults in England. Broader reimbursement and improved access to targeted medicines are expected to support treatment uptake and market growth.

Myasthenia Gravis Market Trends

Some of the major market trends include personalized treatment, self-administration, targeted therapies, and improved patient support.

Rising Adoption of Self-Administration Is Likely to Enhance Market Growth

The market is witnessing several trends, including personalized treatment, self-administration, targeted therapies, and improved patient support. Patient-centric treatment models are increasingly emphasizing convenience, independence, and reduced treatment burden. For instance, in April 2026, UCB presented clinical data on an investigational zilucoplan auto-injector designed for self-administration in adults with anti-acetylcholine receptor antibody-positive generalized disease. Such administration innovations can improve treatment convenience and align therapy with patient preferences, supporting greater adoption and market growth.

Myasthenia Gravis Market Share

Generalized Segment Expected to Lead the Market

The market is segmented by disease type into ocular myasthenia gravis and generalized myasthenia gravis. Generalized myasthenia gravis is expected to lead, supported by its broader clinical burden, greater treatment requirements, and increasing availability of targeted therapies. Approximately 85% of patients with myasthenia gravis experience progression to generalized manifestations. For instance, in April 2025, Johnson & Johnson received U.S. Food and Drug Administration approval for IMAAVY for adults and pediatric patients aged 12 years and older with antibody-positive generalized disease. Expanding treatment options are expected to strengthen segment growth.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Myasthenia Gravis Market Analysis by Region

The countries included in the analysis are the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these countries, the United States is expected to lead, supported by a substantial patient population, advanced healthcare infrastructure, and rapid adoption of targeted therapies. For instance, in April 2025, Johnson & Johnson received U.S. Food and Drug Administration approval for IMAAVY for antibody-positive generalized disease in adults and patients aged 12 years and older. The approval broadens treatment availability and is expected to reinforce U.S. market growth.

Leading Players in the Myasthenia Gravis Market

Myasthenia Gravis Market Segmentation

Key Questions Answered in the Myasthenia Gravis Market Report

• What was the myasthenia gravis market value in 2025?
• What is the myasthenia gravis market forecast outlook for 2026-2035?
• What are the major factors aiding the myasthenia gravis market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major myasthenia gravis market trends?
• Which disease type is expected to dominate the market segment?
• Which treatment type is projected to lead the market segment?
• Which end user is anticipated to drive the market segment?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players involved in the myasthenia gravis market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews with neurologists, neuromuscular specialists, myasthenia gravis treatment experts, healthcare procurement managers, and payer representatives across the United States, EU5, Japan, and India, incorporating insights from clinical and healthcare organizations.
• Secondary Research: Peer-reviewed literature and clinical publications; regulatory information from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), and Central Drugs Standard Control Organization (CDSCO); clinical trial records from ClinicalTrials.gov; and epidemiological data from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and Global Burden of Disease studies. Company information is also reviewed from official corporate websites, including product and pipeline pages.
• Validation: Market estimates are triangulated through top-down and bottom-up modeling, cross-checked against epidemiological, treatment, pricing, and company-level data, and validated through expert feedback loops.